Livensa (testosterone)
- Region
- 🇪🇺 EU
- Active substance
- testosterone
- Company
- Warner Chilcott Deutschland GmbH
- Status
- Withdrawn
- Therapeutic area
- Sexual Dysfunctions, Psychological
- EU approval
- Fri 28 Jul 2006
- Application
- EMEA/H/C/000630
- ATC
- G03BA03
- Official record
- www.ema.europa.eu
Indication
Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Intrinsa Withdrawn · Warner Chilcott UK Ltd.
Follow Livensa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.